Coronary Restenosis

• 

  Subject Areas on Research

  • 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial. 
  • A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. 
  • ALOX5AP variants are associated with in-stent restenosis after percutaneous coronary intervention. 
  • Angiotensin-converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: identifying the guideposts for navigating the genetics landscape. 
  • Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
  • Aspirin and clopidogrel resistance: consideration and management. 
  • Changes in health-related quality of life in off-pump versus on-pump cardiac surgery: Veterans Affairs Randomized On/Off Bypass trial. 
  • Clinical and angiographic efficacy of a self-expanding nitinol stent in saphenous vein graft atherosclerotic disease: the Stent Comparative Restenosis (SCORES) Saphenous Vein Graft Registry. 
  • Clinical and angiographic outcomes with sirolimus-eluting stents in total coronary occlusions: the ACROSS/TOSCA-4 (Approaches to Chronic Occlusions With Sirolimus-Eluting Stents/Total Occlusion Study of Coronary Arteries-4) trial. 
  • Clinical and angiographic predictors of short- and long-term ischemic events in acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. 
  • Clinical and economic outcomes of liberal versus selective drug-eluting stent use: insights from temporal analysis of the multicenter Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry. 
  • Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry. 
  • Clinical end points in coronary stent trials: a case for standardized definitions. 
  • Clinical outcomes in the percutaneous coronary intervention of in-stent restenosis with everolimus-eluting stents. 
  • Clinical utility of serial and continuous ST-segment recovery assessment in patients with acute ST-elevation myocardial infarction: assessing the dynamics of epicardial and myocardial reperfusion. 
  • Combining clinical and angiographic variables for estimating risk of target lesion revascularization after drug eluting stent placement. 
  • Comparative effectiveness of drug-eluting stents on long-term outcomes in elderly patients treated for in-stent restenosis: a report from the National Cardiovascular Data Registry. 
  • Coronary Circulatory Indexes Before and After Percutaneous Coronary Intervention in a Porcine Tandem Stenoses Model. 
  • Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials. 
  • Culprit-only or multivessel revascularization in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report. 
  • Decision models for assessing the cost effectiveness of drug-eluting stents. 
  • Downstream coronary effects of drug-eluting stents. 
  • Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease. 
  • Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomised controlled trials. 
  • ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007. 
  • Early carotid artery stenting and angioplasty in patients with acute ischemic stroke. 
  • Effect of coronary target lesion revascularization on late cardiac events after insertion of sirolimus-eluting or bare metal stents. 
  • Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. 
  • Femoropopliteal In-Stent Restenosis. 
  • Five-year follow-up of the Sirolimus-Eluting Stents vs Vascular Brachytherapy for Bare Metal In-Stent Restenosis (SISR) trial. 
  • Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial. 
  • Gone but not forgotten: the case for drug-eluting stents in percutaneous revascularization of the chronic coronary total occlusion. 
  • Guideline adjudicated fibrinolytic failure: incidence, findings, and management in a contemporary clinical trial. 
  • Highlights from the American Heart Association annual scientific sessions 2001: November 11 to 14, 2001. 
  • Hospital percutaneous coronary intervention volume and outcome: does it matter? 
  • Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial). 
  • Impact of internal mammary artery conduit on long-term outcomes after percutaneous intervention of saphenous vein graft. 
  • Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. 
  • In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. 
  • In-stent pseudo-restenosis due to an organized thrombus six months after implantation of a sirolimus-eluting stent. 
  • Interpreting the music of drug-eluting stents: halcyon song or albatross dirge? 
  • Intracoronary brachytherapy: time to sell short? 
  • Intravascular ultrasound insights from the Cobalt Chromium Stent With Antiproliferative for Restenosis II (COSTAR II) trial comparing CoStar and Taxus paclitaxel-eluting stents. 
  • Is Paclitaxel Causing Mortality During Lower-Extremity Revascularization? 
  • Late adverse events after drug-eluting stent implantation. 
  • Late thrombosis following treatment of in-stent restenosis with drug-eluting stents after discontinuation of antiplatelet therapy. 
  • Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). 
  • Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies. 
  • Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials. 
  • Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease (TIGRIS) observational study. 
  • Lower Repeat Revascularization Rates Among Patients With Prior Coronary Artery Bypass Graft Surgery are Due to Lack of Adequate Target Vessels. 
  • Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. 
  • Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease. 
  • Molecular approaches for the treatment of atherosclerosis. 
  • Native coronary disease progression exceeds failed revascularization as cause of angina after five years in the Bypass Angioplasty Revascularization Investigation (BARI). 
  • Next-generation drug-eluting stents: a spirited step forward or more of the same. 
  • Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Outcomes of second revascularization procedures after stent implantation. 
  • Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. 
  • Percutaneous coronary intervention in native arteries versus bypass grafts in prior coronary artery bypass grafting patients: a report from the National Cardiovascular Data Registry. 
  • Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. 
  • Predicting restenosis of drug-eluting stents placed in real-world clinical practice: derivation and validation of a risk model from the EVENT registry. 
  • Predicting the future of human gene therapy for cardiovascular diseases: what will the management of coronary artery disease be like in 2005 and 2010? 
  • Preprocedural white blood cell count and major adverse cardiac events late after percutaneous coronary intervention in saphenous vein grafts. 
  • Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial. 
  • Provisional vs. complex stenting strategy for coronary bifurcation lesions: meta-analysis of randomized trials. 
  • Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting. 
  • Rapid adoption of drug-eluting stents: clinical practices and outcomes from the early drug-eluting stent era. 
  • Rationale and design of the East-West late lumen loss study: Comparison of late lumen loss between Eastern and Western drug-eluting stent study cohorts. 
  • Relationship of genetic variability and depressive symptoms to adverse events after coronary artery bypass graft surgery. 
  • Repeat revascularization after PCI: are we reinventing the wheel or redefining Achilles' heel? 
  • Repeat revascularization after contemporary percutaneous coronary intervention: an evaluation of staged, target lesion, and other unplanned revascularization procedures during the first year. 
  • Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. 
  • Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery. 
  • Single versus multiple internal mammary artery grafting for coronary artery bypass: 15-year follow-up of a clinical practice trial. 
  • Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. 
  • Stress imaging use and repeat revascularization among medicare patients with high-risk coronary artery disease. 
  • Surrogates, substudies, and real clinical end points in trials of drug-eluting stents. 
  • Temporal trends in target vessel revascularization in clinical practice: long-term outcomes following coronary stenting from the Duke Database for Cardiovascular Disease. 
  • The Cobalt chromium STent with Antiproliferative for Restenosis II (COSTAR II) trial study design: advancing the active-control evaluation of second-generation drug-eluting stents. 
  • The process of bringing new drug-eluting stents to market will they see the light of day? 
  • The relation between clinical features, angiographic findings, and the target lesion revascularization rate in patients receiving the endeavor zotarolimus-eluting stent for treatment of native coronary artery disease: an analysis of ENDEAVOR I, ENDEAVOR II, ENDEAVOR II Continued Access Registry, and ENDEAVOR III. 
  • The role of hyaluronic acid in atherosclerosis and intimal hyperplasia. 
  • Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography: A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis. 
  • Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. 
• 

  Keywords of People

  • Brennan, J. Matthew, Associate Professor of Medicine, Medicine, Cardiology
  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine